Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality – results from two surveys (2016)

E.J. Aspinall, S.J. Hutchinson, D.J. Goldberg, H. Valerio, A. Mozalevskis, T. Noori, E. Duffell, L. Tavoschi

Research output: Contribution to journalArticle

27 Downloads (Pure)

Abstract

Objectives
The World Health Organization (WHO) developed a European Regional Action Plan (EAP) to fasttrack action towards the goal of eliminating viral hepatitis. Robust monitoring is essential to assess national programme performance. The purpose of this study was to assess the availability of selected monitoring data sources in European Union/European Economic Area (EU/EEA) Member States (MS).

Methods
Availability of data sources at EU/EEA level was assessed using two surveys distributed to 31 EU/EEA MS in 2016. The two surveys covered (A) availability of policy documents on testing; testing practices and monitoring; monitoring of diagnosis and treatment initiation, and; (B) availability of data on mortality attributable to chronic viral hepatitis.

Results
Just over two-thirds of EU/EEA MS responded to the surveys. 86% (18/21) reported national testing guidance covering HBV, and 81% (17/21) covering HCV; while 33% (7/21) and 38% (8/21) of countries, respectively, monitored the number of tests performed. 71% (15/21) of countries monitored the number of chronic HBV cases diagnosed and 33% (7/21) the number of people treated. Corresponding figures for HCV were 48% (10/21) and 57% (12/21). 27% (6/22) of countries reported availability of data on mortality attributable to chronic viral hepatitis.

Conclusions
The results of this study suggest that sources of information in EU/EEA Member States to monitor the progress towards the EAP milestones and targets related to viral hepatitis diagnosis, cascade of care and attributable mortality are limited. Our analysis should raise awareness among EU/EEA policy makers and stimulate higher prioritisation of efforts to improve the monitoring of national viral hepatitis programmes.
Original languageEnglish
Pages (from-to)11-15
Number of pages5
JournalHIV Medicine
Volume19
Issue numberS1
DOIs
Publication statusPublished - 28 Feb 2018

Fingerprint

European Union
Chronic Hepatitis
Hepatitis C
Hepatitis B
Economics
Mortality
Hepatitis
Information Storage and Retrieval
Administrative Personnel
Surveys and Questionnaires

Keywords

  • hepatitis B
  • hepatitis C

Cite this

@article{7a15dc06d4a04a599cc4c2af57453ea0,
title = "Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality – results from two surveys (2016)",
abstract = "ObjectivesThe World Health Organization (WHO) developed a European Regional Action Plan (EAP) to fasttrack action towards the goal of eliminating viral hepatitis. Robust monitoring is essential to assess national programme performance. The purpose of this study was to assess the availability of selected monitoring data sources in European Union/European Economic Area (EU/EEA) Member States (MS).MethodsAvailability of data sources at EU/EEA level was assessed using two surveys distributed to 31 EU/EEA MS in 2016. The two surveys covered (A) availability of policy documents on testing; testing practices and monitoring; monitoring of diagnosis and treatment initiation, and; (B) availability of data on mortality attributable to chronic viral hepatitis.ResultsJust over two-thirds of EU/EEA MS responded to the surveys. 86{\%} (18/21) reported national testing guidance covering HBV, and 81{\%} (17/21) covering HCV; while 33{\%} (7/21) and 38{\%} (8/21) of countries, respectively, monitored the number of tests performed. 71{\%} (15/21) of countries monitored the number of chronic HBV cases diagnosed and 33{\%} (7/21) the number of people treated. Corresponding figures for HCV were 48{\%} (10/21) and 57{\%} (12/21). 27{\%} (6/22) of countries reported availability of data on mortality attributable to chronic viral hepatitis.ConclusionsThe results of this study suggest that sources of information in EU/EEA Member States to monitor the progress towards the EAP milestones and targets related to viral hepatitis diagnosis, cascade of care and attributable mortality are limited. Our analysis should raise awareness among EU/EEA policy makers and stimulate higher prioritisation of efforts to improve the monitoring of national viral hepatitis programmes.",
keywords = "hepatitis B , hepatitis C",
author = "E.J. Aspinall and S.J. Hutchinson and D.J. Goldberg and H. Valerio and A. Mozalevskis and T. Noori and E. Duffell and L. Tavoschi",
note = "Acceptance from webpage Published version free access, rather than open access; AAM rec'd 170718 DC. AAM: 12m embargo Exception status: agreed no exception can be applied (library exception review, October 2018)",
year = "2018",
month = "2",
day = "28",
doi = "10.1111/hiv.12599",
language = "English",
volume = "19",
pages = "11--15",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "S1",

}

Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality – results from two surveys (2016). / Aspinall, E.J.; Hutchinson, S.J.; Goldberg, D.J.; Valerio, H.; Mozalevskis, A.; Noori, T.; Duffell, E.; Tavoschi, L.

In: HIV Medicine, Vol. 19, No. S1, 28.02.2018, p. 11-15.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality – results from two surveys (2016)

AU - Aspinall, E.J.

AU - Hutchinson, S.J.

AU - Goldberg, D.J.

AU - Valerio, H.

AU - Mozalevskis, A.

AU - Noori, T.

AU - Duffell, E.

AU - Tavoschi, L.

N1 - Acceptance from webpage Published version free access, rather than open access; AAM rec'd 170718 DC. AAM: 12m embargo Exception status: agreed no exception can be applied (library exception review, October 2018)

PY - 2018/2/28

Y1 - 2018/2/28

N2 - ObjectivesThe World Health Organization (WHO) developed a European Regional Action Plan (EAP) to fasttrack action towards the goal of eliminating viral hepatitis. Robust monitoring is essential to assess national programme performance. The purpose of this study was to assess the availability of selected monitoring data sources in European Union/European Economic Area (EU/EEA) Member States (MS).MethodsAvailability of data sources at EU/EEA level was assessed using two surveys distributed to 31 EU/EEA MS in 2016. The two surveys covered (A) availability of policy documents on testing; testing practices and monitoring; monitoring of diagnosis and treatment initiation, and; (B) availability of data on mortality attributable to chronic viral hepatitis.ResultsJust over two-thirds of EU/EEA MS responded to the surveys. 86% (18/21) reported national testing guidance covering HBV, and 81% (17/21) covering HCV; while 33% (7/21) and 38% (8/21) of countries, respectively, monitored the number of tests performed. 71% (15/21) of countries monitored the number of chronic HBV cases diagnosed and 33% (7/21) the number of people treated. Corresponding figures for HCV were 48% (10/21) and 57% (12/21). 27% (6/22) of countries reported availability of data on mortality attributable to chronic viral hepatitis.ConclusionsThe results of this study suggest that sources of information in EU/EEA Member States to monitor the progress towards the EAP milestones and targets related to viral hepatitis diagnosis, cascade of care and attributable mortality are limited. Our analysis should raise awareness among EU/EEA policy makers and stimulate higher prioritisation of efforts to improve the monitoring of national viral hepatitis programmes.

AB - ObjectivesThe World Health Organization (WHO) developed a European Regional Action Plan (EAP) to fasttrack action towards the goal of eliminating viral hepatitis. Robust monitoring is essential to assess national programme performance. The purpose of this study was to assess the availability of selected monitoring data sources in European Union/European Economic Area (EU/EEA) Member States (MS).MethodsAvailability of data sources at EU/EEA level was assessed using two surveys distributed to 31 EU/EEA MS in 2016. The two surveys covered (A) availability of policy documents on testing; testing practices and monitoring; monitoring of diagnosis and treatment initiation, and; (B) availability of data on mortality attributable to chronic viral hepatitis.ResultsJust over two-thirds of EU/EEA MS responded to the surveys. 86% (18/21) reported national testing guidance covering HBV, and 81% (17/21) covering HCV; while 33% (7/21) and 38% (8/21) of countries, respectively, monitored the number of tests performed. 71% (15/21) of countries monitored the number of chronic HBV cases diagnosed and 33% (7/21) the number of people treated. Corresponding figures for HCV were 48% (10/21) and 57% (12/21). 27% (6/22) of countries reported availability of data on mortality attributable to chronic viral hepatitis.ConclusionsThe results of this study suggest that sources of information in EU/EEA Member States to monitor the progress towards the EAP milestones and targets related to viral hepatitis diagnosis, cascade of care and attributable mortality are limited. Our analysis should raise awareness among EU/EEA policy makers and stimulate higher prioritisation of efforts to improve the monitoring of national viral hepatitis programmes.

KW - hepatitis B

KW - hepatitis C

U2 - 10.1111/hiv.12599

DO - 10.1111/hiv.12599

M3 - Article

VL - 19

SP - 11

EP - 15

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - S1

ER -